Kinase Inhibitors from Early Research to Clinic

24th June 2010
 AstraZeneca, Alderley Park Conference Centre, Alderley Park, Macclesfield
Programme:
 
09.00 Arrival, Registration and Coffee
Session 1 - Chair: Andrew Ratcliffe
09.50    Prof Andrew Wilks, SYN|thesis med chem, Australia
Kinase research in the 21st century - where is it going?
10.45 Dr Gerhard Mueller, Proteros Fragments GmbH, Germany
On the pitfalls of reductionism in today’s kinase inhibitor design
11.30 Tea
11.50 Dr Karen Leach, Pfizer, USA
Small molecule kinase inhibitor promiscuity: Translating kinase selectivity profiles into early safety guidance
12.35 Lunch

Session 2 - Chair: Steve Collingwood
13.45 Dr Iain Kilty, Pfizer, UK
JAK inhibitors as novel anti-inflammatory agents
14.30 Dr Matthew Thomas, Novartis, UK
Inhibitors of PDGFR kinase as a novel therapy for pulmonary arterial hypertension
15.15 Tea
Session 3 - Chair: Jack Allen
15.40

Dr Paul Smith, AstraZeneca , UK
Understanding and combating resistance to MEK inhibition
16.25 Dr Ken Thress, AstraZeneca , USA
Trk kinase inhibitors - Identification of novel small molecules with potential for cross-therapeutic utility in both oncology and OA-induced pain
17.15 Closing remarks and thanks
 

Back to Menu


Home / Meetings / Membership / Student Bursaries / Administration / 
History of the SMR / SMR Award / Archive Material / Links / Contact Us